Clinical observation on the treatment of hypercholesterolemia and carotid arteriosclerosis in extremely high risk or high risk cardiovascular disease patients with PCSK9 inhibitors
Objective To observe the clinical effects of PCSK9 inhibitors in the treatment of hypercholesterolemia and carotid atherosclerosis in extremely high-risk or high-risk cardiovascular disease patients.Methods A total of 82 patients with high cardiovascular risk or high risk of hypercholesterolemia in Nanchang Third Hospital from October 2021 to March 2022 were retrospectively selected as the study objects and divided into group A(16 cases),group B(33 cases)and group C(33 cases)according to treatment methods.All patients were treated with atorvastatin calcium tablets.On this basis,patients in group A were treated with placebo injection,patients in group B were treated with abdominal subcutaneous injection of 300 mg of AK102 injection,and patients in group C were treated with subcutaneous injection of 450 mg of AK102 injection.Blood lipids,carotid intima-media thickness,plaque size and the incidence of adverse events were compared among the three groups.Results The levels of total cholesterol(TC),low-density lipoprotein cholesterol(LDL-C),triglycerides(TG),apolipoprotein B(ApoB)and lipoprotein(a)(Lp[a])in the three groups after treatment were lower than those before treat-ment,with statistically significant differences(P＜0.05).The levels of TC,LDL-C,TG and ApoB in group B and group C were lower than those in group A,with statistically significant differences(P＜0.05).The levels of TC,LDL-C,TG and ApoB in group C were lower than those in group B,with statistically significant differences(P＜0.05).High-density lipopro-tein cholesterol(HDL-C)levels in the three groups after treatment were higher than those before treatment,with statistically significant differences(P＜0.05),but there was no signifi-cant difference in HDL-C among the groups(P＞0.05).The carotid intima-media thickness and plaque size in the three groups after treatment were smaller than those before treatment,with statistically significant differences(P＜0.05).Plaques in group B and group C after treatment were smaller than those in group A,with statistically significant differences(P＜0.05),but there was no significant difference between group B and group C(P＞0.05).During the treatment,there was no statistically significant difference in the incidence of adverse events such as creatine kinase elevation,transaminase ab-normality,muscle soreness and diarrhea among the three groups(P＞0.05).Conclusion PCSK9 inhibitors can significantly lower LDL-C level in extremely high or high-risk cardiovascular disease patients with hypercholesterolemia,with good lipid-lowering effect.In addition,they can slow down the development of carotid atherosclerosis.
HypercholesterolemiaCarotid arteriosclerosisCardiovascular diseaseProprotein convertase subtilisin/Kexin type 9 inhibitor
万方数据
维普
